The global transthyretin amyloidosis treatment market
Robust pipeline of transthyretin amyloidosis treatment drugs is one of the major factors that is expected to propel growth of the market over the forecast period. Request Sample Copy: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4586 The global transthyretin amyloidosis treatment market accounted for US$ 40.5 million in 2019 and is anticipated to register a CAGR of 58.7%. The report " Global Transthyretin Amyloidosis Treatment Market, By Drug ( Inostersen, Partisiran, Tafamidis, and Others ), By Indication ( Wild Type ATTR Amyloidosis, and Hereditary ATTR Amyloidosis ), By Distribution Channel ( Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy ), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029” . Key Highlights: In August 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPA...